Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of rosiglitazone maleate and metformin hydrochloride in the presence of interfering matrix excipients. (September 2014)
- Record Type:
- Journal Article
- Title:
- Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of rosiglitazone maleate and metformin hydrochloride in the presence of interfering matrix excipients. (September 2014)
- Main Title:
- Development and validation of spectrophotometric and HPTLC methods for simultaneous determination of rosiglitazone maleate and metformin hydrochloride in the presence of interfering matrix excipients
- Authors:
- Mahgoub, Hoda
Youssef, Rasha M.
Korany, Mohamed A.
Khamis, Essam F.
Kamal, Miranda F. - Abstract:
- <abstract> <title>Abstract</title> <p>Two simple methods have been developed and validated for the simultaneous determination of rosiglitazone maleate (ROS) and metformin hydrochloride (MET) in synthetic mixtures and coated tablets in a ratio of 1:250 (ROS:MET). The first method was a spectrophotometric one. The minor component, ROS was determined by measuring the values of absorbance at <italic>λ</italic><sub>max</sub> 312 nm and the <italic>D</italic><sub>1</sub> amplitudes at 331 nm where MET shows no absorption contribution. However, absorbance interferences from tablet excipients were successfully corrected by <italic>D</italic><sub>1</sub> at 331 nm zero-crossing technique. Study of spectral interference from tablet excipients was included in the text. Standard curves for <italic>A</italic><sub>max</sub> and <italic>D</italic><sub>1</sub> methods were in the concentration range 20.0–80.0 μg mL<sup>−1</sup>. The major component, MET was determined both in binary mixtures and tablets by measuring its <italic>A</italic><sub>max</sub> at 236 nm. Extensive dilution eliminated any absorption contribution from the coexisting ROS or tablet matrix. Standard curves showed linearity in the concentration range 4.0–12.8 μg mL<sup>−1</sup>. The second method was based on high performance thin layer chromatography (HPTLC) separation of the two drugs followed by densitometric measurements of their spots at 230 nm. The separation was carried out on Merck HPTLC aluminium sheets of<abstract> <title>Abstract</title> <p>Two simple methods have been developed and validated for the simultaneous determination of rosiglitazone maleate (ROS) and metformin hydrochloride (MET) in synthetic mixtures and coated tablets in a ratio of 1:250 (ROS:MET). The first method was a spectrophotometric one. The minor component, ROS was determined by measuring the values of absorbance at <italic>λ</italic><sub>max</sub> 312 nm and the <italic>D</italic><sub>1</sub> amplitudes at 331 nm where MET shows no absorption contribution. However, absorbance interferences from tablet excipients were successfully corrected by <italic>D</italic><sub>1</sub> at 331 nm zero-crossing technique. Study of spectral interference from tablet excipients was included in the text. Standard curves for <italic>A</italic><sub>max</sub> and <italic>D</italic><sub>1</sub> methods were in the concentration range 20.0–80.0 μg mL<sup>−1</sup>. The major component, MET was determined both in binary mixtures and tablets by measuring its <italic>A</italic><sub>max</sub> at 236 nm. Extensive dilution eliminated any absorption contribution from the coexisting ROS or tablet matrix. Standard curves showed linearity in the concentration range 4.0–12.8 μg mL<sup>−1</sup>. The second method was based on high performance thin layer chromatography (HPTLC) separation of the two drugs followed by densitometric measurements of their spots at 230 nm. The separation was carried out on Merck HPTLC aluminium sheets of silica gel 60 F254 using methanol:water:NH<sub>4</sub>Cl 1% w/v (5:4:1 v/v/v) as the mobile phase. Linear calibration graphs of peak area values were obtained versus concentrations in the range of 0.4–2.0 μg band<sup>−1</sup> and 20.0–100.0 μg band<sup>−1</sup> for ROS and MET, respectively. According to International Conference on Harmonisation (ICH) guidelines, different validation parameters were verified for the two methods and presented.</p> </abstract> … (more)
- Is Part Of:
- Drug development and industrial pharmacy. Volume 40:Number 9(2014:Sep.)
- Journal:
- Drug development and industrial pharmacy
- Issue:
- Volume 40:Number 9(2014:Sep.)
- Issue Display:
- Volume 40, Issue 9 (2014)
- Year:
- 2014
- Volume:
- 40
- Issue:
- 9
- Issue Sort Value:
- 2014-0040-0009-0000
- Page Start:
- 1190
- Page End:
- 1198
- Publication Date:
- 2014-09
- Subjects:
- Pharmaceutical chemistry -- Periodicals
Pharmaceutical industry -- Periodicals
Drug Industry -- Periodicals
Technology, Pharmaceutical -- Periodicals
615.05 - Journal URLs:
- http://informahealthcare.com/loi/ddi ↗
http://informahealthcare.com ↗ - DOI:
- 10.3109/03639045.2013.810634 ↗
- Languages:
- English
- ISSNs:
- 0363-9045
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.116000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3260.xml